CD8A and neoplasm: Recent studies have shown that simultaneous inhibition of T-cell immunoreceptor with Ig and ITIM domains (TIGIT) and PD-L1 can promote the CD226-driven expansion of tumor-reactive CD8 T cells from tumor-draining lymph nodes (TDLNs) into the peripheral blood, followed by their infiltration into tumor sites.